While Arcutis Biotherapeutics Inc has overperformed by 2.07%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARQT rose by 52.28%, with highs and lows ranging from $13.17 to $1.76, whereas the simple moving average jumped by 28.57% in the last 200 days.
On August 28, 2024, Jefferies started tracking Arcutis Biotherapeutics Inc (NASDAQ: ARQT) recommending Buy. A report published by Mizuho on January 03, 2024, Upgraded its rating to ‘Buy’ for ARQT. Mizuho also Downgraded ARQT shares as ‘Neutral’, setting a target price of $4 on the company’s shares in a report dated October 26, 2023. Goldman October 13, 2023d the rating to Neutral on October 13, 2023, and set its price target from $32 to $6. Needham initiated its ‘Buy’ rating for ARQT, as published in its report on September 07, 2022. Goldman’s report from March 17, 2022 suggests a price prediction of $45 for ARQT shares, giving the stock a ‘Buy’ rating. Mizuho also rated the stock as ‘Buy’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Arcutis Biotherapeutics Inc (ARQT)
Further, the quarter-over-quarter increase in sales is 494.57%, showing a positive trend in the upcoming months.
Arcutis Biotherapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -148.92% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.19, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and ARQT has an average volume of 2.42M. On a monthly basis, the volatility of the stock is set at 7.03%, whereas on a weekly basis, it is put at 6.26%, with a loss of -4.60% over the past seven days. Furthermore, long-term investors anticipate a median target price of $18.57, showing growth from the present price of $10.37, which can serve as yet another indication of whether ARQT is worth investing in or should be passed over.
How Do You Analyze Arcutis Biotherapeutics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 13.25%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 99.47% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ARQT shares are owned by institutional investors to the tune of 99.47% at present.
